Digital Cognitive Assessments
New Tools for Cognitive Testing and Diagnosis
Rising cases of mild cognitive impairment (MCI) and dementia combined with persistent underdiagnosis are driving a need for scalable, accessible cognitive assessment tools. Digital cognitive assessments (DCAs) offer a promising solution that can enhance routine cognitive testing and open the door to early, accurate diagnosis for patients.
Major Benefits of DCAs
Current research shows DCAs hold promising potential to overcome common challenges with conventional cognitive tests.
Accessible
DCAs can help clinicians detect signs of possible cognitive impairment. DCAs have the potential to be used in more care settings than traditional cognitive assessments with additional language and accessibility considerations.
Insightful
DCAs can be leveraged across several clinical contexts to aid in a particular diagnosis, to characterize the level of cognitive impairment, and to develop a cognitive profile. They have the potential to reduce variability and provide more insights compared to traditional analog assessments.
DCAs as Part of an Integrated Approach to Cognitive Assessments
Incorporating DCAs into clinical practice can empower clinicians to better detect cognitive impairment, address causes and risk factors, and develop treatment plans that support patient needs.
To facilitate broader implementation in primary and specialty care, it is critical that health systems and healthcare providers are prepared, educated, and informed about this diagnostic tool – and that expert consensus is reached for the acceptable standards of clinically used DCAs and the rationale for these recommendations.
Access the DCA Billing Code Primer
Read the Latest Diagnostic News and Insights
news web part will go here
Read the Latest
Diagnostic News and Insights
View More News & Insights Here
FDA Grants Breakthrough Device Designation to pTau 217 Blood Test for Alzheimer Disease
Go To Resource
About the Digital Cognitive Assessment Workgroup
The Global CEO Initiative on Alzheimer’s Disease (CEOi) is leading a global effort to prepare for the adoption of digital cognitive assessments in clinical care so patients experience a more simple, timely, and accurate diagnostic experience. The DCA Workgroup comprises 200+ experts with a diverse array of backgrounds, including experts from health systems, academia, industry, digital health, diagnostic vendor organizations, patient advocacy, and payers.